Latest News
Clinical Trials Roundup | 21 Aug 2026
Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
Latest News
The Preclinical Bottleneck: Why Traditional Antibody Discovery Hits a Wall
The therapeutic landscape has been undeniably transformed by monoclonal antibodies (mAbs). From oncology to autoimmune disorders and emerging infectious diseases, mAbs represent one of the most powerful modalities in modern medicine. However, the initial phase of...
Exploring the Role of Astrocytes in MND With Translatable Human Cell Models
Motor Neuron Disease (MND) is characterised by the progressive loss of motor neurons. Despite years of research into the disease, effective treatments remain extremely limited and half of patients pass away within two years of diagnosis. To date there is no cure for...
Clinical Trials Roundup | 24 July 2026
Merck's enlicitide receives FDA approval as the first oral PCSK9 inhibitor for adults with hypercholesterolaemia, GSK's zidesamtinib earns FDA approval as a next-generation ROS1 selective inhibitor for previously treated non-small cell lung cancer, GSK's camlipixant...
New Platform Pairly’s Rapid Growth Highlights Urgent Need to Simplify UK Social Care
An entrepreneur whose father died before care at home could be arranged has built a digital platform that is transforming how families find care across the UK. After experiencing first-hand how difficult it was to arrange support for his own father, Pairly co-founder...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Tumor Vasculature has Long Been a Target. Measuring it is the Next Step
Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
When ADHD and Menopause Overlap
When ADHD and Menopause Overlap: Why Midlife Women Are Still Not Getting the Right Answers Girls and women have historically been overlooked in the ADHD diagnostic process and this is due, in part, to the fact that their symptoms often present differently than they do...
How Rapid Access MRI Can Reshape Diagnostic Pathways
It’s no secret that the National Health Service (NHS) is suffering diagnostic pressure. The British Medical Association (BMA) reports that in November 2024, approximately 1.6 million people in England were waiting for a diagnostic test. That’s double the 0.8...
Panthera Biopartners Expands European Footprint
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Inside the Science: The Hydrogel Injection Targeting NHS Knee Care
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS A new white paper entitled “Inside the Science: A Major Step Forward for Knee...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
NHS England First in World to Offer Blenrep for Myeloma
Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Weekly News Roundup | 20 April 2026
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
Tumor Vasculature has Long Been a Target. Measuring it is the Next Step
Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
When ADHD and Menopause Overlap
When ADHD and Menopause Overlap: Why Midlife Women Are Still Not Getting the Right Answers Girls and women have historically been overlooked in the ADHD diagnostic process and this is due, in part, to the fact that their symptoms often present differently than they do...
How Rapid Access MRI Can Reshape Diagnostic Pathways
It’s no secret that the National Health Service (NHS) is suffering diagnostic pressure. The British Medical Association (BMA) reports that in November 2024, approximately 1.6 million people in England were waiting for a diagnostic test. That’s double the 0.8...
Panthera Biopartners Expands European Footprint
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Inside the Science: The Hydrogel Injection Targeting NHS Knee Care
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS A new white paper entitled “Inside the Science: A Major Step Forward for Knee...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
NHS England First in World to Offer Blenrep for Myeloma
Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Weekly News Roundup | 20 April 2026
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
Featured Articles
Further News
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Daraxonrasib Phase 3 Trial Results Signal a New Era for Pancreatic Cancer
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
How Can At-Home Diagnostics and AI-Enabled Detection Drive Better Health?
The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
The Gut Microbiome and the Future of Human Health
The gut microbiome has moved from a niche area of research to one of the most important frontiers in modern medicine. Once associated mainly with digestion, it is now understood to be a complex, organ-like system that influences immunity, metabolism and even brain...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.